Sign in
Taking people in United StatesEarly phase 1

Imaging study of a PET tracer in Parkinson's, MSA and healthy adults

Tests a PET scan tracer in adults with Parkinson disease, multiple system atrophy or healthy.

Key facts

Who runs it
MODAG GmbH
Where
New Haven, United StatesSee the site
Trial code
Registry title
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
Status
Recruiting
Phase
Early phase 1
People taking part
13 people, planned
Started
13 May 2026
Expected to end
May 2027
Type of study
Interventional
Treatments tested
  • [¹⁸F]MODAG-009 PET imaging
Record updated
10 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Parkinson's disease, including early (prodromal) forms, adults with multiple system atrophy (MSA), and healthy adults. All are in the PPMI study (MSA volunteers are not required to be).

Age
50 to 80 years (healthy controls and MSA: 50 to 75; Parkinson's: 50 to 80).
Sex
All genders can join.
Disease stage
Parkinson's disease or prodromal Parkinson's, or MSA that is clinically established or clinically probable. Healthy controls must have no significant brain disease and a MDS-UPDRS III score under 6.
Earlier treatment
Must not have taken dopamine receptor blockers (neuroleptics), metoclopramide, lithium or reserpine in the past 6 months. Must not have been in an α-synuclein drug trial in the past 6 months.
Biomarker or test result
Spinal fluid α-synuclein seed amplification assay (SAA): negative for healthy controls, positive for Parkinson's and MSA. MSA also needs signs of nigrostriatal degeneration on a DaTscan.

Main reasons for not taking part

  • Signs of other brain-degenerating diseases, such as Alzheimer's disease
  • Cannot safely have a lumbar puncture, for example because of bleeding problems or blood thinners that cannot be held
  • Cannot safely have MRI or DaTscan, for example severe claustrophobia or metal implants
  • Known allergy to DaTscan or iodine-containing premedication
  • Other medical or psychiatric problems that the investigator thinks prevent taking part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Healthy Controls inclusion criteria:; Enrolled in the PPMI 002 Clinical study as a healthy control participant; Any gender aged 50 to 75 years of age; Negative CSF α-synuclein seed amplification assay (SAA); Previously acquired (since inclusion in PPMI) brain MRI without evidence of significant neurological pathology; Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) score of <6 at the last PPMI annual visit which is within the past 18 months; Cognitively intact with Montreal Cognitive Assessment (MoCA) greater than or equal to 26 at the last PPMI annual visit which was within the past 18 months
  • Parkinson's Disease and Prodromal PD inclusion criteria:; Enrolled in the PPMI 002 Clinical study as a Parkinson's Disease (PD) or Prodromal participant; Any gender aged 50 to 80 years of age; Positive CSF SAA; A current or previously acquired brain MRI (since the onset of motor symptoms for PD or since enrolled in PPMI for the prodromal PD) without evidence of significant neurological pathology other than changes expected for PD; Montreal Cognitive Assessment (MoCA) greater than or equal to 24 at the last PPMI annual visit which was within the past 18 months
  • Multiple System Atrophy (MSA) inclusion criteria:; Any gender aged 50 to 75 years of age; Clinically established MSA or Clinically Probable MSA according to the Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (Wenning et al., 2022); Positive CSF SAA; A current or previously acquired brain MRI (since the onset of motor symptoms attributed to MSA) without evidence of significant neurological pathology other than the pathology expected for MSA; Evidence of nigrostriatal degeneration on DaTscan obtained at screening or on previously acquired imaging since the onset of the motor symptoms attributed to MSA

Who cannot take part

  • All Cohorts:; Clinical evidence of other neurodegenerative diseases, such as Alzheimer's disease; Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation; Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide, lithium and reserpine, within 6 months of Baseline Visit; Any other reason that in the opinion of the investigator, including abnormal labs, that could interfere with the safety with radiotracer injection, would render the participant unsuitable for the study enrollment; Participation in an investigational drug trial targeting α-synuclein within the past 6 months prior to enrollment; Currently being treated with and unable to safely hold antiplatelets (other than low dose aspirin up to 100mg/day) or anticoagulants prior to the procedure that might preclude safe attempt of Lumbar puncture, if applicable; Condition that precludes the safe performance of routine lumbar puncture, if applicable, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant and uncorrected coagulopathy or thrombocytopenia; Conditions or medications that preclude safe performance of imaging procedures (MRI or DaTscan), including but not limited to severe claustrophobia, MRI-incompatible metal implants, or known hypersensitivity to imaging agents; Known hypersensitivity to DaTscan or iodine-containing compounds used as premedication for DaTscan. Participants with iodine sensitivity may still complete the imaging without iodine premedication at the investigator's discretion; Use of medications known to interfere with DaTscan imaging (e.g., bupropion, amphetamines, methylphenidate, modafinil, alpha-methyldopa), unless the participant is willing and medically able to hold the medication for at least 5 half-lives or specified duration per investigators judgement prior to imaging

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 80 years old?

Where in United States

  • Institute for Neurodegenerative Disorders and XingImaging, LLCNew Haven, United StatesContact: Mackenzee GeorgeTaking people

About the trial

What the trial wants to find out

This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of [¹⁸F]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study. Each participant will receive a single intravenous injection of [¹⁸F]MODAG-009, followed by PET imaging using the investigational United Imaging NeuroEXPLORER (NX) camera.

The group in the trial

  • Parkinson's disease (PD); Multiple system atrophy (MSA); Healthy controls (HC)Treatment being tested

    Participants enrolled in the study will receive a single IV injection of up to up to 8 mCi of \[¹⁸F\]MODAG-009.

    Treatment: [¹⁸F]MODAG-009 PET imaging

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
Plain-language title
Imaging study of a PET tracer in Parkinson's, MSA and healthy adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07640555, who can take part
Record updated
10 June 2026